France
PROMISE Proteomics, founded in 2010 and headquartered in France, is a leading player in the biotechnology, health care, and pharmaceutical industries. The company specializes in the bioproduction of Stable Isotope Labelled monoclonal antibodies and proteins, serving as internal standards for absolute quantification by mass spectrometry.
The company's offerings encompass two key areas:
1. Stable Isotope Labelled and Unlabelled Proteins and Monoclonal Antibodies: PROMISE Proteomics provides a wide range of products and services for customized bioproduction of stable isotope labelled and unlabelled proteins and monoclonal antibodies, catering to diverse research and development needs.
2. Innovative Kits for Monoclonal Antibody Quantification: The company's mAbXmise kits are designed for monoclonal antibody quantification by mass spectrometry. These kits are ready-to-use sample preparation solutions, inclusive of stable-labelled monoclonal antibodies as internal standards, along with all necessary reagents and consumables. mAbXmise targets 20 t-mAbs on the market, covering various therapeutic areas.
PROMISE Proteomics' dedication to advancing biotherapies monitoring by mass spectrometry is encapsulated in its slogan: "Next generation of biotherapies monitoring by mass spectrometry." While specific investment details are not currently available, the company's innovative approach and significant presence in key industries make it an intriguing prospect for potential venture capital opportunities within the biotechnology and pharmaceutical sectors.
